标题
Combination strategies to enhance antitumor ADCC
作者
关键词
-
出版物
Immunotherapy
Volume 4, Issue 5, Pages 511-527
出版商
Future Medicine Ltd
发表日期
2012-05-29
DOI
10.2217/imt.12.38
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Combinations of the immunocytokine F16-IL2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumors.
- (2017) F. G. De Braud et al. JOURNAL OF CLINICAL ONCOLOGY
- Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
- (2014) Liat Binyamin et al. JOURNAL OF IMMUNOLOGY
- Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF- 1
- (2014) H. Li et al. JOURNAL OF IMMUNOLOGY
- Session 13: indolent lymphoma
- (2011) ANNALS OF ONCOLOGY
- IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR
- (2011) M. P. Roberti et al. BREAST CANCER RESEARCH AND TREATMENT
- Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours
- (2011) A J Nicol et al. BRITISH JOURNAL OF CANCER
- Immunomodulating antibodies and drugs for the treatment of hematological malignancies
- (2011) Roch Houot et al. CANCER AND METASTASIS REVIEWS
- Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment
- (2011) Shangzi Wang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance
- (2011) Xiaoping Huang et al. CANCER LETTERS
- TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers
- (2011) R. Rosa et al. CLINICAL CANCER RESEARCH
- A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
- (2011) T. K. Eigentler et al. CLINICAL CANCER RESEARCH
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- Epigenetic Modulation Enhances the Therapeutic Effect of Anti-IL-13R 2 Antibody in Human Mesothelioma Xenografts
- (2011) M. Takenouchi et al. CLINICAL CANCER RESEARCH
- CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
- (2011) C. Zoglmeier et al. CLINICAL CANCER RESEARCH
- Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
- (2011) Pier Luigi Zinzani et al. Clinical Lymphoma Myeloma & Leukemia
- The predictive significance of CD20 expression in B-cell lymphomas
- (2011) Veronika Prevodnik et al. Diagnostic Pathology
- Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression
- (2011) Esther Moga et al. EXPERIMENTAL HEMATOLOGY
- Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
- (2011) Yuting Ma et al. JOURNAL OF EXPERIMENTAL MEDICINE
- IL-12 Enhances the Antitumor Actions of Trastuzumab via NK Cell IFN- Production
- (2011) A. C. Jaime-Ramirez et al. JOURNAL OF IMMUNOLOGY
- Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
- (2011) G S Nowakowski et al. LEUKEMIA
- Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma
- (2011) Reem Karmali et al. LEUKEMIA & LYMPHOMA
- Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
- (2011) Clive S. Zent et al. LEUKEMIA & LYMPHOMA
- Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia
- (2011) Christian W. Eskelund et al. LEUKEMIA RESEARCH
- Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells
- (2011) Malin Dahl et al. MOLECULAR BIOLOGY REPORTS
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy
- (2010) Christopher F. Nicodemus et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Fc R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
- (2010) K. Tamura et al. ANNALS OF ONCOLOGY
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)
- (2010) Michael Croft Annual Review of Immunology
- New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
- (2010) Tadeusz Robak et al. BIODRUGS
- CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
- (2010) H. E. Kohrt et al. BLOOD
- Human T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement
- (2010) A. Maniar et al. BLOOD
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients
- (2010) Raphaël Maréchal et al. BMC CANCER
- Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
- (2010) Y C Cheng et al. BRITISH JOURNAL OF CANCER
- Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
- (2010) Lei Wu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Genotypes of NK Cell KIR Receptors, Their Ligands, and Fc Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy
- (2010) D. C. Delgado et al. CANCER RESEARCH
- Targeting T Lymphocytes for Cancer Immunotherapy: From Novel Mechanistic Insight to Clinical Application
- (2010) A. Q. Gomes et al. CANCER RESEARCH
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- CD16 cross-linking induces increased expression of CD56 and production of IL-12 in peripheral NK cells
- (2010) Maria-Elena Márquez et al. CELLULAR IMMUNOLOGY
- Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study
- (2010) Julie E. Chang et al. Clinical Lymphoma Myeloma & Leukemia
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells☆☆☆
- (2010) Jun Nakajima et al. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
- B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression
- (2010) Andrea Borgerding et al. EXPERIMENTAL HEMATOLOGY
- T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
- (2010) M. S. Braza et al. HAEMATOLOGICA
- Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
- (2010) William G. Wierda et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study
- (2010) Suzanne Shusterman et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report
- (2010) Stacey L. Berg et al. JOURNAL OF CLINICAL ONCOLOGY
- CD11c+ Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors
- (2010) N. M. Haynes et al. JOURNAL OF IMMUNOLOGY
- A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL
- (2010) J R Brown et al. LEUKEMIA
- HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
- (2010) R Shimizu et al. LEUKEMIA
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
- (2010) Alice L. Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD20-Targeted Therapy: The Next Generation of Antibodies
- (2010) Tom van Meerten et al. SEMINARS IN HEMATOLOGY
- Macrophages as mediators of tumor immunosurveillance
- (2010) Siddhartha Jaiswal et al. TRENDS IN IMMUNOLOGY
- Improvement of Rituximab Efficiency in Chronic Lymphocytic Leukemia by CpG-Mediated Upregulation of CD20 Expression Independently of PU.1
- (2009) Amani Mankaï et al. Annals of the New York Academy of Sciences
- Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies
- (2009) J. Gertner-Dardenne et al. BLOOD
- CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas
- (2009) E. A. Rossi et al. BLOOD
- Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells
- (2009) F. Romagne et al. BLOOD
- GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells
- (2009) Johanna K. Morales et al. BREAST CANCER RESEARCH AND TREATMENT
- Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma
- (2009) M Watanabe et al. BRITISH JOURNAL OF CANCER
- Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
- (2009) Kristie A. Blum et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma
- (2009) Jonathan W. Friedberg et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis
- (2009) Xuzhang Lu et al. CANCER SCIENCE
- A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action
- (2009) V. Damiano et al. CLINICAL CANCER RESEARCH
- Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC
- (2009) Atsushi Inagaki et al. INTERNATIONAL JOURNAL OF CANCER
- Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- (2009) Thomas E. Witzig et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- IL-15 Renders Conventional Lymphocytes Resistant to Suppressive Functions of Regulatory T Cells through Activation of the Phosphatidylinositol 3-Kinase Pathway
- (2009) M. B. Ahmed et al. JOURNAL OF IMMUNOLOGY
- Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma
- (2009) David J. Betting et al. JOURNAL OF IMMUNOTHERAPY
- Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists
- (2009) Svetlana Hamm et al. Journal of Immunotoxicology
- Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
- (2009) Antoni Ribas et al. Journal of Translational Medicine
- Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
- (2009) A Poggi et al. LEUKEMIA
- A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
- (2009) T. S. Bekaii-Saab et al. MOLECULAR CANCER THERAPEUTICS
- Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies
- (2008) W. Lin et al. BLOOD
- A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab
- (2008) Aruna Mani et al. BREAST CANCER RESEARCH AND TREATMENT
- IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma
- (2008) Klaus Stensgaard Frederiksen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma
- (2008) Jaafar Bennouna et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Interleukin 21 Enhances Antibody-Mediated Tumor Rejection
- (2008) M. J. Smyth et al. CANCER RESEARCH
- Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti-neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice
- (2008) S. Sharma et al. CANCER RESEARCH
- Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors
- (2008) M. Vales-Gomez et al. CANCER RESEARCH
- Opposing effects of interferon-α and interferon-γ on the expression of major histocompatibility complex class I chain-related A in tumors
- (2008) Cai Zhang et al. CANCER SCIENCE
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
- (2008) L. Wu et al. CLINICAL CANCER RESEARCH
- Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab
- (2008) Hirotake Tokuyama et al. INTERNATIONAL JOURNAL OF CANCER
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study
- (2008) Guillaume Cartron et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group
- (2008) Eva Kimby et al. LEUKEMIA & LYMPHOMA
- Up on the tightrope: natural killer cell activation and inhibition
- (2008) Lewis L Lanier NATURE IMMUNOLOGY
- NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma
- (2007) Esther Moga et al. EXPERIMENTAL HEMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started